Acrivon Therapeutics (ACRV) Return on Assets (2022 - 2026)
Acrivon Therapeutics (ACRV) posted quarterly Return on Assets of 0.01% for Q1 2026, little changed year-over-year from 0.01% in Q1 2025, and down 11.79% quarter-over-quarter from 0.01% in Q4 2025.
Acrivon Therapeutics (ACRV) Return on Assets (2022 - 2026) Analysis & Trends
Acrivon Therapeutics (ACRV) has reported Return on Assets for 5 consecutive years, with 0.01% the latest figure, recorded in Q1 2026.
- In Q1 2026, Return on Assets changed 0.0% year-over-year to 0.01%; the TTM figure through Mar 2026 stood at 0.01% (changed 0.0% YoY), while the FY2025 annual figure was 0.01%, changed 0.0% from the prior year.
- Return on Assets declined to 0.01% in Q1 2026 per ACRV's latest filing, from 0.01% in the prior quarter.
- Across five years, Return on Assets topped out at 0.0% in Q4 2022 and bottomed at 0.01% in Q1 2024.
- Historically, Return on Assets has averaged 0.01% across 5 years, with a median of 0.01% in 2025.
- Annual changes were most pronounced in 2023 — Return on Assets decreased 1 bps — and 2024, when it changed 0 bps.
- Acrivon Therapeutics' Return on Assets stood at 0.0% in 2022, then sank by 183 bps to 0.01% in 2023, then jumped by 34 bps to 0.01% in 2024, then declined by 19 bps to 0.01% in 2025, then decreased by 12 bps to 0.01% in 2026.
- Business Quant data shows ACRV's Return on Assets at 0.01% in Q1 2026, 0.01% in Q4 2025, and 0.01% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROA (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.84 Bn | 131.99 Bn | 2.84 Bn | 0.00% |
| 2 | Regeneron Pharmaceuticals | 86.48 Bn | 78.49 Bn | 3.93 Bn | 0.00% |
| 3 | Argenx Se | 65.47 Bn | 60.29 Bn | 1.37 Bn | - |
| 4 | Moderna | 60.15 Bn | 55.01 Bn | 52.00 Mn | 0.00% |
| 5 | BeOne Medicines | 42.22 Bn | 37.12 Bn | 1.53 Bn | 0.00% |
| 6 | Alnylam Pharmaceuticals | 31.67 Bn | 28.36 Bn | 992.69 Mn | 0.00% |
| 7 | BioNTech SE | 28.54 Bn | 10.14 Bn | 668.28 Mn | 0.00% |
| 8 | Insmed | 27.58 Bn | 26.42 Bn | 358.27 Mn | 0.00% |
| 9 | Royalty Pharma | 27.22 Bn | 26.38 Bn | - | 0.00% |
| 10 | Acrivon Therapeutics | 96.24 Mn | 96.24 Mn | - | -0.01% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -0.01% |
| Mar 31, 2026 | -0.01% |
| Dec 31, 2025 | -0.01% |
| Sep 30, 2025 | -0.01% |
| Jun 30, 2025 | -0.01% |
| Mar 31, 2025 | -0.01% |
| Dec 31, 2024 | -0.01% |
| Sep 30, 2024 | 0.00% |
| Jun 30, 2024 | -0.01% |
| Mar 31, 2024 | -0.01% |
| Dec 31, 2023 | -0.01% |
| Sep 30, 2023 | -0.01% |
| Jun 30, 2023 | -0.01% |
| Mar 31, 2023 | 0.00% |
| Dec 31, 2022 | 0.00% |